Prognostic factors on univariate analysis in 73 patients who underwent resection for malignant IPMT
| Variable | Patients (n) | p Value* | Odds ratio (95% CI) |
|---|---|---|---|
| *Log rank test, number of patients for each variable compared with remaining patients. †Data available. IPMT, intraductal papillary mucinous tumours of the pancreas; CEA, carcinoembryonic antigen; CA 19.9, carbohydrate antigen 19-9; NS, p>0.05. N, upper limit of the normal laboratory value. ‡Also significant in multivariate analysis. | |||
| Sex: male | 49 | NS | |
| Age >65 y | 41 | NS | |
| First symptom | |||
| Acute pancreatitis | 20 | NS | |
| Abdominal pain | 13 | 0.004 | 3.3 (1.4 to 7.7) |
| Jaundice | 12 | NS | |
| CEA (n=38)† ≥2N | 6 | NS | |
| CA 19.9 (n=46)† ≥2N | 17 | 0.02 | 2.7 (1.1 to 6.6) |
| Tumour location | |||
| Head/corpus | 49 | 0.01 | 0.3 (0.1 to 0.8) |
| Tail | 14 | 0.04 | 2.3 (1.0 to 5.2) |
| Diffuse | 6 | NS | |
| Duct involvement | |||
| Main duct or combined | 65 | NS | |
| Secondary ducts only | 8 | NS | |
| Tumour size (n=60)† >30 mm | 21 | NS | |
| Pathology | |||
| In situ carcinoma | 22 | 0.01 | 6.3 (1.5 to 27.0) |
| Invasive carcinoma | 51 | ||
| Pancreatic cut surface | |||
| Normal | 50 | NS | |
| Hyperplasia | 9 | NS | |
| Atypical hyperplasia | 7 | NS | |
| In situ carcinoma | 4 | NS | |
| Invasive carcinoma | 3 | NS | |
| Colloid form (n=51)† | 33 | NS | |
| Lymph node metastases | 17 | 0.0001‡ | 7.5 (3.4 to 16.4) |
| Peripancreatic extension: T3 | 12 | 0.01 | 2.8 (1.2 to 6.8) |
| Malignant relapse | 28 | 0.0001 | 9.0 (3.4 to 24.0) |
| Adjuvant treatment: radio/chemotherapy | 7 | NS | |
| Centre | |||
| Clichy | 24 | NS | |
| Lyon | 23 | NS | |
| Paris | 20 | NS | |
| Marseille | 6 | NS | |